At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Post-Market Trading 05-16 16:02:31 EDT
1.03
-0.05
-4.63%
High1.08Low1.03Vol228.02K
Open1.07D1 Closing1.08Amplitude4.63%
Mkt Cap38.73MTradable Cap17.09MTotal Shares37.61M
T/O237.53KT/O Rate1.37%Tradable Shares16.59M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)
TIPRANKS  ·  05-16 01:30
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
GlobeNewswire  ·  05-15 11:03
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
Unicycive Therapeutics reports Q1 GAAP EPS of -$0.61
seekingalpha  ·  05-15 00:36
Unicycive Therapeutics reports Q1 GAAP EPS of -$0.61
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
TIPRANKS  ·  05-14 23:40
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Noble Financial Remains a Buy on Unicycive Therapeutics (UNCY)
TIPRANKS  ·  05-14 20:25
Noble Financial Remains a Buy on Unicycive Therapeutics (UNCY)
Piper Sandler Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)
TIPRANKS  ·  05-14 19:21
Piper Sandler Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire  ·  05-14 04:16
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
TipRanks  ·  04-30
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
TIPRANKS  ·  04-12
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
StreetInsider  ·  04-10
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD
TIPRANKS  ·  04-04
Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Benzinga  ·  04-01
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
TIPRANKS  ·  04-01
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M
seekingalpha  ·  03-29
Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire  ·  03-28
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-25
Calendar of U.S. Earnings Expected in the Week Ahead
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
GlobeNewswire  ·  03-25
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors
Reuters  ·  03-15
BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--